Company profile
Mesenbio
Using mesenchymal stem cells to produce therapeutically meaningful extracellular vesicles.
- Industry
- Biotechnology Research
- Employees
- 13
- Headquarters
- York
- Founded
- 2021
- Office locations
- 1
Mesenbio company summary
Mesenbio is a company in the Biotechnology Research industry, headquartered in York, founded in 2021. On LinkedIn the company has around 13 employees. Its listed specialties include Biotechnology, Extracellular Vesicles, Exosomes, Mesenchymal Stem Cells, Mesenchymal Stromal Cells.
What technology does Mesenbio use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Mesenbio
We are a recently incorporated limited company, spun out from the University of York from the Genever lab (www.geneverlab.info), which has over 20 years of experience in cell biology and regenerative medicine. We focus on musculoskeletal regeneration using mesenchymal stem cells (MSCs), with a view to translate our body of work into cutting edge therapeutics. Our current focal point is the field of extracellular vesicles (EVs), which have recently gained substantial traction as a next-generation therapeutic modality. We believe that current approaches have room for improvement in terms of consistency and efficacy, which is where we come in. Our suite of immortal MSC lines represent an endless source of therapeutically active EVs, eliminating the need for donor source material. Combined with an in-house chemically defined medium, we can provide improved batch consistency, while reducing cost of goods and reducing regulatory burden. Our initial target is osteoarthritis, which presents an unprecedented socioeconomic burden as populations age and no disease modifying drugs exist. With our MSC-derived EVs, we have shown that we can exert a strong anti-inflammatory effect, with the added capability of specific cargo delivery. Our MSC-EV production platform is an agile, versatile means of producing therapeutic EVs for any application at improved consistency.
Specialties
Where is Mesenbio located?
Mesenbio lists 1 location.
Compare companies similar to Mesenbio
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Mesenbio mesenbio.net | Biotechnology Research | 13 | 2021 | York |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about Mesenbio
What does Mesenbio do?
We are a recently incorporated limited company, spun out from the University of York from the Genever lab (www.geneverlab.info), which has over 20 years of experience in cell biology and regenerative medicine. We focus on musculoskeletal regeneration using mesenchymal stem cells (MSCs), with a view to translate our body of work into cutting edge therapeutics. Our current focal point is the field of extracellular vesicles (EVs), which have recently gained substantial traction as a next-generation therapeutic modality. We believe that current approaches have room for improvement in terms of consistency and efficacy, which is where we come in. Our suite of immortal MSC lines represent an endless source of therapeutically active EVs, eliminating the need for donor source material. Combined with an in-house chemically defined medium, we can provide improved batch consistency, while reducing cost of goods and reducing regulatory burden. Our initial target is osteoarthritis, which presents an unprecedented socioeconomic burden as populations age and no disease modifying drugs exist. With our MSC-derived EVs, we have shown that we can exert a strong anti-inflammatory effect, with the added capability of specific cargo delivery. Our MSC-EV production platform is an agile, versatile means of producing therapeutic EVs for any application at improved consistency.
How many employees does Mesenbio have?
Mesenbio has around 13 employees on LinkedIn.
Where is Mesenbio headquartered?
Mesenbio is headquartered in York.
When was Mesenbio founded?
Mesenbio was founded in 2021.
Build a lead list from companies like Mesenbio
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.